Beigene's (ONC) "Outperform" Rating Reiterated at Royal Bank of Canada

Beigene (NASDAQ:ONC - Get Free Report)'s stock had its "outperform" rating restated by research analysts at Royal Bank of Canada in a research note issued on Monday,Benzinga reports. They presently have a $312.00 price target on the stock. Royal Bank of Canada's price target would indicate a potential upside of 24.87% from the stock's previous close.

Several other analysts also recently issued reports on ONC. Macquarie lifted their price target on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on Beigene in a research report on Thursday, March 13th. Guggenheim reaffirmed a "buy" rating on shares of Beigene in a research report on Wednesday, April 16th. JPMorgan Chase & Co. upped their price target on Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Finally, Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and increased their target price for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Beigene presently has a consensus rating of "Buy" and an average price target of $318.88.

Beigene Stock Performance

ONC traded up $4.95 during trading on Monday, reaching $249.85. 77,397 shares of the stock were exchanged, compared to its average volume of 485,873. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The business's 50 day moving average price is $247.84. Beigene has a twelve month low of $141.31 and a twelve month high of $287.88. The company has a market cap of $24.70 billion, a PE ratio of -30.32, a P/E/G ratio of 7.73 and a beta of 0.49.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Equities research analysts predict that Beigene will post -5.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Xiaobin Wu sold 30,654 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the firm's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now directly owns 730,642 shares in the company, valued at approximately $189,966,920. The trade was a 50.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,146,048 shares of company stock worth $295,198,300 in the last three months. 6.62% of the stock is owned by corporate insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.